// App-Quantinova.ai

329 : Selinexor or KPT-8602 mediated XPO1 inhibition synergizes with dexamethasone to repress convergent pathways in the mTORC1 signaling network and drive cell death in multiple myeloma

Researchers

Presenter

  • Christian Argueta

Principal Investigators

  • Trinayan Kashyap

  • Boris Klebanov

  • Hua Chang

  • Sharon Friedlander

  • Erkan Baloglu

  • Yosef Landesman

  • Margaret Lee

  • Humphrey Gardner

  • Sharon Shacham

  • William Senapedis

Medical Centers

  • Karyopharm Therapeutics, Newton, MA

Locations

  • United States

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Exportin 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Selinexor

  • KPT-8602

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved